Skip to content

Developing and Implementing HPV SCREENED

Developing and Implementing HPV SCREENED (Self-Collection REach and ENgagement in Emergency Departments) to Improve Cancer Equity

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07657104
Enrollment
100
Registered
2026-06-18
Start date
2026-08-20
Completion date
2027-09-30
Last updated
2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer Screening, Human Papilloma Virus

Brief summary

This study will assess the feasibility of implementing HPV self-sampling as a primary cervical cancer screening strategy for under-screened women in the emergency department (ED). Eligible participants will receive education and an HPV self-sampling kit to complete in the ED. Individuals with HPV-positive results will be guided to follow-up care at a local clinic.

Detailed description

The proposed study will implement HPV self-sampling as primary cervical screening for under-screened ED patients. The long-term goal is to increase access to cervical screening for women who may not routinely use primary care and thus face increased risk of cervical cancer. This pilot feasibility trial will implement HPV self-sampling kit distribution and navigation to follow-up care in the ED. The investigators hypothesize that ED-based in-person distribution and same-day return of HPV self-sampling kits will alleviate issues of prior mailed HPV self-sampling trials by reducing participant burden. Women (30-65 years with non-critically ill presentations) who present to the ED and are overdue for cervical screening will receive 1) cervical cancer screening education and 2) a HPV self-sampling kit where they return the kit immediately after self-sampling in the ED. ScreenNJ will navigate participants with HPV-positive results to follow-up care and management according to current standard guidelines at local clinics.

Interventions

BEHAVIORALHPV Self-collection in the ED

Participants will be asked to collect a vaginal sample for HPV screening.

Sponsors

Rutgers, The State University of New Jersey
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* biological women, * no prior hysterectomy or cervical cancer, * not pregnant, * last Pap \>3 years, last co-test \>5 years, or last HPV alone test \>5 years, * speak English or Spanish, * has a working cellphone, * NJ residency * ED patient

Exclusion criteria

* currently pregnant (as diagnostic procedures for cervical cancer are often deferred during pregnancy); * previous hysterectomy; * previous diagnosis of cervical cancer; * current menses

Design outcomes

Primary

MeasureTime frameDescription
Completion of ED-Based HPV Self-SamplingDay 1Evaluate the proportion of eligible participants who complete HPV self-sampling during the emergency department visit.

Secondary

MeasureTime frameDescription
HPV Self Sampling AcceptabilityAfter results notification, an average of 1 weekAcceptability of Intervention Measure (AIM) scale (Weiner et al., 2017). Scale values range from 1 to 5, where higher is more acceptable.
HPV Self Sampling FeasibilityAfter results notification, an average of 1 weekFeasibility of Intervention Measure (FIM) scale (Weiner et al., 2017). Scale values range from 1 to 5, where higher is more feasible.
HPV KnowledgeDay 1 and after results notification- an average of 1 weekCervical Cancer Knowledge Scale (CCKS)- 7 items where a higher score is more knowledge
Screening Completion3 monthsProportion of HPV+ women who complete follow-up screening

Countries

United States

Contacts

CONTACTSara Heinert, PhD, MPH
sara.heinert@rutgers.edu(732) 235-7872
PRINCIPAL_INVESTIGATORSara Heinert, PhD, MPH

Department of Emergency Medicine, Rutgers Robert Wood Johnson Medical School

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 12, 2026